Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Back to Search
Print
Bookmark Trial

NCT02135029

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Creekside Endocrine Associates, PC
Denver, Colorado, 80209, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hyperlipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Hyperlipidemia

- Statin Intolerant

- Fasting LDL-C > = 70 mg/dL Fasting TG < = 400 mg/dL

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pregnant or breastfeeding females


- Cardiovascular or cerebrovascular event or procedure within 90 days


- Severe or life-threatening adverse events with past use of statins


- Poorly controlled hypertension

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

HyperlipidemiaThe Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.
NCT00172419
  1. Taipei,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
HyperlipidemiaRandomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
NCT02100514
  1. Alexander City, Alabama
  2. Auburn, Alabama
  3. Phoenix, Arizona
  4. Phoenix, Arizona
  5. Tucson, Arizona
  6. Tucson, Arizona
  7. Little Rock, Arkansas
  8. Little Rock, Arkansas
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Norwalk, California
  13. Sacramento, California
  14. Sacramento, California
  15. Santa Rosa, California
  16. Tustin, California
  17. Ventura, California
  18. Aurora, Colorado
  19. Colorado Springs, Colorado
  20. Denver, Colorado
  21. Boca Raton, Florida
  22. Boca Raton, Florida
  23. Brooksville, Florida
  24. Coral Gables, Florida
  25. Fort Lauderdale, Florida
  26. Hialeah, Florida
  27. Hialeah, Florida
  28. Miami Beach, Florida
  29. Miami Lakes, Florida
  30. Miami Lakes, Florida
  31. Miami, Florida
  32. Miami, Florida
  33. Miami, Florida
  34. Miami, Florida
  35. Miami, Florida
  36. Miami, Florida
  37. Miami, Florida
  38. Miramar, Florida
  39. Ocala, Florida
  40. Ocala, Florida
  41. Pembroke Pines, Florida
  42. Pembroke Pines, Florida
  43. Pembroke Pines, Florida
  44. Port Orange, Florida
  45. Port Orange, Florida
  46. Saint Augustine, Florida
  47. Saint Augustine, Florida
  48. Saint Petersburg, Florida
  49. Sarasota, Florida
  50. Tampa, Florida
  51. Boise, Idaho
  52. Avon, Indiana
  53. Augusta, Kansas
  54. Wichita, Kansas
  55. Wichita, Kansas
  56. Wichita, Kansas
  57. Lake Charles, Louisiana
  58. Metairie, Louisiana
  59. Monroe, Louisiana
  60. Bethesda, Maryland
  61. Elkridge, Maryland
  62. Flint, Michigan
  63. Saint Cloud, Minnesota
  64. Saint Cloud, Minnesota
  65. Picayune, Mississippi
  66. Saint Louis, Missouri
  67. Saint Louis, Missouri
  68. Fremont, Nebraska
  69. Portsmouth, New Hampshire
  70. Albuquerque, New Mexico
  71. Greenville, North Carolina
  72. Greenville, North Carolina
  73. Greenville, North Carolina
  74. Hickory, North Carolina
  75. Hickory, North Carolina
  76. Hickory, North Carolina
  77. Raleigh, North Carolina
  78. Raleigh, North Carolina
  79. Dayton, Ohio
  80. Perrysburg, Ohio
  81. Oklahoma City, Oklahoma
  82. Tulsa, Oklahoma
  83. Harleysville, Pennsylvania
  84. Wyomissing, Pennsylvania
  85. Charleston, South Carolina
  86. Columbia, South Carolina
  87. Spartanburg, South Carolina
  88. Germantown, Tennessee
  89. Jackson, Tennessee
  90. Jackson, Tennessee
  91. Knoxville, Tennessee
  92. Carrollton, Texas
  93. Houston, Texas
  94. Houston, Texas
  95. Houston, Texas
  96. Katy, Texas
  97. Missouri City, Texas
  98. Plano, Texas
  99. San Antonio, Texas
  100. Sugar Land, Texas
  101. Orem, Utah
  102. Arlington, Virginia
  103. Norfolk, Virginia
  104. Port Orchard, Washington
  105. Port Orchard, Washington
  106. Walla Walla, Washington
  107. Kenosha, Wisconsin
  108. Manitowoc, Wisconsin
  109. Calgary, Alberta
  110. Burnaby, British Columbia
  111. Kamloops, British Columbia
  112. Kelowna, British Columbia
  113. Langley, British Columbia
  114. New Westminster, British Columbia
  115. Penticton, British Columbia
  116. Vancouver, British Columbia
  117. Victoria, British Columbia
  118. Barrie, Ontario
  119. Brampton, Ontario
  120. Brampton, Ontario
  121. Corunna, Ontario
  122. Etobicoke, Ontario
  123. Markham, Ontario
  124. Newmarket, Ontario
  125. Oakville, Ontario
  126. Oshawa, Ontario
  127. Peterborough, Ontario
  128. Scarborough, Ontario
  129. Thornhill, Ontario
  130. Toronto, Ontario
  131. Toronto, Ontario
  132. Toronto, Ontario
  133. Chicoutimi, Quebec
  134. Greenfield Park, Quebec
  135. Longueuil, Quebec
  136. Montreal, Quebec
  137. Saint-Georges, Beauce, Quebec
  138. Trois-Rivieres, Quebec
  139. Trois-Rivieres, Quebec
  140. Quebec,
  141. Quebec,
  142. Trutnov, Kralovehradecky KRAJ
  143. Praha 10, Vinohrady
  144. Brno,
  145. Brno,
  146. Kladno,
  147. Kladno,
  148. Kromeriz,
  149. Olomouc,
  150. Olomouc,
  151. Olomouc,
  152. Olomouc,
  153. Praha 4,
  154. Praha 4,
  155. Pribram,
  156. Pribram,
  157. Slany,
  158. Slany,
  159. Teplice,
  160. Teplice,
  161. Trutnov,
  162. Lappeenranta,
  163. Turku,
  164. Anyang-si, Gyeonggi-do
  165. Guri-si, Gyeonggi-do
  166. Busan,
  167. Seoul,
  168. Enschede, ER
  169. Amsterdam, North Holland
  170. Apeldoorn,
  171. Eindhoven,
  172. Enschede,
  173. Gorinchem,
  174. Groningen,
  175. Heerlen,
  176. Rotterdam,
  177. Rotterdam,
  178. Sneek,
  179. Tilburg,
  180. Utrecht,
  181. Honefoss,
  182. Oslo,
  183. Oslo,
  184. Lublin, Lubelskie
  185. Zamosc, Lubelskie
  186. Staszow, Swietokrzyskie
  187. Gdynia,
  188. Grodzisk Mazowiecki,
  189. Katowice,
  190. Katowice,
  191. Krakow,
  192. Lodz,
  193. Olawa,
  194. Poznan,
  195. Pulawy,
  196. Warszawa,
  197. Wroclaw,
  198. Wroclaw,
  199. Ponce,
  200. Ponce,
  201. Rio Grande,
  202. Singapore,
  203. Singapore,
  204. Goteborg,
  205. Lessebo,
  206. Linkoping,
  207. Lund,
  208. Lund,
  209. Rattvik,
  210. Stockholm,
  211. Stockholm,
  212. Reading, Berkshire
  213. Salford, Greater Manchester
  214. Glasgow, Lanarkshire Scotland
  215. Chorley, Lancashire
  216. Hexham, Northumberland
  217. Worcester, Worcestershire
  218. Ayr,
  219. Birmingham,
  220. Hull,
  221. Liverpool,
  222. Manchester,
  223. Swansea,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HyperlipidemiaAssess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
NCT00139061
  1. Angers,
  2. Angers,
  3. Bordeaux Cauderan,
  4. Briollay,
  5. Dijon,
  6. Hagondange,
  7. Haut Mauco,
  8. Jarny,
  9. Lille,
  10. Mars LA Tour,
  11. Metz,
  12. Monguilhem,
  13. Mont de Marsan CEDEX,
  14. Mont de Marsan,
  15. Mont de Marsan,
  16. Mont de Marsan,
  17. Moutiers,
  18. Murs Erigne,
  19. Nantes,
  20. Pouilly en Auxois,
  21. Saint Justin,
  22. Saint Martin D'Oney,
  23. Seysses,
  24. Strasbourg,
  25. Thouars,
  26. Tierce,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HyperlipidemiaCompliance With Treatment For Patients With Hyperlipidemia
NCT00828945
  1. Akersberga,
  2. Forshaga,
  3. Goteborg,
  4. Goteborg,
  5. Goteborg,
  6. Hoganas,
  7. Jonkoping,
  8. Lessebo,
  9. Lilla Edet,
  10. Limhamn,
  11. Malmo,
  12. Oviken,
  13. Partille,
  14. Stockholm,
  15. Taby,
  16. Trollhattan,
  17. Vasteras,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
Official Title  ICMJE A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins
Brief Summary This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Hyperlipidemia
Intervention  ICMJE
  • Drug: Bococizumab (PF-04950615;RN316)
    150 mg every 2 weeks by subcutaneous injection for 24 weeks
  • Drug: Atorvastatin
    Atorvastatin PO QD
  • Other: Placebo for Bococizumab (PF-04950615;RN316)
    150 mg every 2 weeks by subcutaneous injection for 24 weeks
  • Other: Placebo for atorvastatin
    PO QD
Study Arms  ICMJE
  • Experimental: Bococizumab (PF-04950615;RN316)
    Bococizumab (PF-04950615;RN316)
    Intervention: Drug: Bococizumab (PF-04950615;RN316)
  • Active Comparator: Atorvastatin
    Intervention: Drug: Atorvastatin
  • Placebo Comparator: Placebo
    Interventions:
    • Other: Placebo for Bococizumab (PF-04950615;RN316)
    • Other: Placebo for atorvastatin
Publications * Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 9, 2015)		184
Original Estimated Enrollment  ICMJE
 (submitted: May 7, 2014)		300
Actual Study Completion Date  ICMJE November 2015
Actual Primary Completion Date November 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Hyperlipidemia
  • Statin Intolerant
  • Fasting LDL-C > = 70 mg/dL Fasting TG < = 400 mg/dL

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • Cardiovascular or cerebrovascular event or procedure within 90 days
  • Severe or life-threatening adverse events with past use of statins
  • Poorly controlled hypertension
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02135029
Other Study ID Numbers  ICMJE B1481030
STATIN INTOLERANT
SPIRE-SI ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP